Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3
Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of.
Mr. Soni Invests $5 Million in Summit while Joining Executive Team
In Corresponding Appointments, Dave Gancarz, Urte Gayko, PhD, Fong Clow, DSc, & Allen S. Yang, MD, PhD, Elevated to Newly.
Summit Therapeutics (SMMT) Appoints Leader Manmeet S Soni as COO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Reata Pharmaceuticals First Quarter 2021 Financial Results and Update on Development Programs Conference Call. An audio recording of today s webcast will be available shortly after the call today on Reata s website at reatapharma.com in the Investors section. Before the company proceeds with its remarks, please note the forward-looking statements disclosure in the company s press release. The company will be making forward-looking statements on today s call. There are many factors that could cause results to differ from expectations, including those noted in the company s SEC filings. On today s conference call, non-GAAP financial measures will be used to help investors understand the business performance.